About OncoCyte
OncoCyte is a company based in Irvine (United States) founded in 2009.. OncoCyte has raised $15.35 million across 11 funding rounds from investors including SG Americas Securities and Pura Vida. The company has 49 employees as of December 31, 2024. OncoCyte has completed 2 acquisitions, including Chronix Biomedical and Insight Genetics. OncoCyte offers products and services including DetermaCNI, DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure. OncoCyte operates in a competitive market with competitors including Oncimmune, Biodesix, Mirvie, Epic Sciences and Miroculus, among others.
- Headquarter Irvine, United States
- Employees 49 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Insight Molecular Diagnostics Inc.
-
Annual Revenue
$1.88 M25.15as on Dec 31, 2024
-
Net Profit
$-60.66 M-118.36as on Dec 31, 2024
-
EBITDA
$-21.68 M-5.32as on Dec 31, 2024
-
Total Equity Funding
$15.35 M (USD)
in 11 rounds
-
Latest Funding Round
$21.74 M (USD), Post-IPO
Feb 10, 2025
-
Investors
SG Americas Securities
& 1 more
-
Employee Count
49
as on Dec 31, 2024
-
Investments & Acquisitions
Chronix Biomedical
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OncoCyte
OncoCyte is a publicly listed company on the NASDAQ with ticker symbol IMDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OncoCyte
OncoCyte offers a comprehensive portfolio of products and services, including DetermaCNI, DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Test to identify immune checkpoint inhibitor responders.
Detects early cancer progression after treatment.
Monitors kidney transplant health via DNA detection.
Monitors liver transplant health through DNA analysis.
Kit for assessing transplant graft health accurately.
Unlock access to complete
Funding Insights of OncoCyte
OncoCyte has successfully raised a total of $15.35M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.74 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $21.7M
-
First Round
First Round
(13 May 2015)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Post-IPO - OncoCyte | Valuation |
investors |
|
| Oct, 2024 | Amount | Post-IPO - OncoCyte | Valuation |
investors |
|
| Apr, 2024 | Amount | Post-IPO - OncoCyte | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OncoCyte
OncoCyte has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include SG Americas Securities and Pura Vida. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Investment management services are provided focusing on healthcare innovation.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OncoCyte
OncoCyte has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Chronix Biomedical and Insight Genetics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Molecular diagnostics company that is working to enhance the diagnosis, monitoring and treatment of cancer.
|
2007 | ||||
|
Non-invasive diagnostics for cancer detection are developed through blood-based tests.
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - OncoCyte
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oncocyte Comparisons
Competitors of OncoCyte
OncoCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oncimmune, Biodesix, Mirvie, Epic Sciences and Miroculus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Diagnostics and risk assessment solutions for lung cancer are developed.
|
|
| domain | founded_year | HQ Location |
Cancer detection diagnostics assays are developed and offered.
|
|
| domain | founded_year | HQ Location |
Non-invasive blood tests for prenatal fetal health predictions are offered.
|
|
| domain | founded_year | HQ Location |
Non-invasive tests for detecting circulating tumor cells are provided.
|
|
| domain | founded_year | HQ Location |
MicroRNA profiling platform is developed to detect genes in samples.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oncocyte
Frequently Asked Questions about OncoCyte
When was OncoCyte founded?
OncoCyte was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Where is OncoCyte located?
OncoCyte is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Who is the current CEO of OncoCyte?
Ron Andrews is the current CEO of OncoCyte.
Is OncoCyte a funded company?
OncoCyte is a funded company, having raised a total of $15.35M across 11 funding rounds to date. The company's 1st funding round was a Post-IPO of $15.81M, raised on May 13, 2015.
How many employees does OncoCyte have?
As of Dec 31, 2024, the latest employee count at OncoCyte is 49.
What is the annual revenue of OncoCyte?
Annual revenue of OncoCyte is $1.88M as on Dec 31, 2024.
What does OncoCyte do?
Founded in 2009 and based in Irvine, United States, non-invasive diagnostic tests for cancer are developed by the company. Operations focus on analyzing blood and urine samples for biomarkers through gene expression patterns compared against a database of known cancers. Tests such as DetermaRx for non-squamous NSCLC and DetermaRx EGFR for early-stage NSCLC are offered, enabling identification of lung, breast, and bladder cancers in the biotechnology sector.
Who are the top competitors of OncoCyte?
What products or services does OncoCyte offer?
OncoCyte offers DetermaCNI, DetermaIO, VitaGraft Kidney, VitaGraft Liver, and GraftAssure.
Is OncoCyte publicly traded?
Yes, OncoCyte is publicly traded on NASDAQ under the ticker symbol IMDX.
How many acquisitions has OncoCyte made?
OncoCyte has made 2 acquisitions, including Chronix Biomedical, and Insight Genetics.
Who are OncoCyte's investors?
OncoCyte has 2 investors. Key investors include SG Americas Securities, and Pura Vida.
What is OncoCyte's ticker symbol?
The ticker symbol of OncoCyte is IMDX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.